you are here: HomeNewsBusiness

Buy Torrent Pharmaceuticals; target of Rs 3290: ICICI Direct

ICICI Direct is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3290 in its research report dated February 09, 2021.

February 10, 2021 / 05:02 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Torrent Pharmaceuticals

Q3 revenues remained flattish (up 1.5% YoY) at Rs 1995 crore (I-direct estimate: Rs 2072 crore) mainly due to 23.4% YoY decline in US formulations to Rs 292 crore. Domestic sales grew 6.8% YoY to Rs 930 crore. Brazil de-grew 8.5% YoY to Rs 173 crore. Germany business grew a robust 21.0% YoY to Rs 265 crore. EBITDA margins expanded 296 bps YoY to 30.4% (I-direct estimate: 30.5%) mainly due to lower other expenses amid lower travel and promotional spends. Subsequently, EBITDA grew 12.4% YoY to Rs 607 crore (I-direct estimate: Rs 632 crore). PAT grew 18.3% YoY to Rs 297 crore (I-direct estimate: Rs 289 crore) in line with operational performance.


We maintain BUY with a TP of Rs 3290 (earlier Rs 3135) based on 32x FY23E EPS of Rs 102.8

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Feb 10, 2021 05:02 pm

stay updated

Get Daily News on your Browser